Keyword Search
 

2017 | 2016 | 2015 | 2014 | 2013
Ocular Therapeutix™ to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference

Ocular Therapeutix™ Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Ocular Therapeutix™ to Report Third Quarter 2017 Financial Results

Ocular Therapeutix™ Appoints Donald Notman as Chief Financial Officer

Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Ocular Therapeutix™ Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality

Ocular Therapeutix™ Announces Antony Mattessich Assumes Role as Chief Executive Officer

Ocular Therapeutix™ to Report Second Quarter 2017 Financial Results

Ocular Therapeutix™ Receives Complete Response Letter from FDA for DEXTENZA™ NDA

Ocular Therapeutix™ Submits Amendment to Potentially Extend Review for DEXTENZA™ New Drug Application (NDA)

Ocular Therapeutix™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Ocular Therapeutix™ Announces Executive Transition Plans

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ Presented Phase 3 Data for DEXTENZA™ at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting

Ocular Therapeutix™ Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix™ Reports First Quarter 2017 Financial Results

Ocular Therapeutix™ to Present Data on Anterior and Posterior Segment Drug Product Candidates at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix™ to Report First Quarter 2017 Financial Results

Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer

New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™ Following Cataract Surgery

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results

Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock

Ocular Therapeutix™ Resubmits NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery

Ocular Therapeutix, Inc. Announces Public Offering of Common Stock

Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™